Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease statusIn a new sub-analysis of the landmark EMPEROR-Preserved ®Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline1 Empagliflozin consistently improved outcomes across the full range of kidney function down to an eGFR of 20 mL/min/1.73 m21
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news